Source: Numstocker / Shutterstock.com
A press release from Baudax Bio reveals that the FDA has approved a new drug application (NDA) for the company. This NDA includes ANJESO, which is a drug used to treat patients suffering from moderate to severe pain.
FDA approval allows the drug to be used in combination with other non-NSAIDs. The drug is administered once a day via an intravenous (IV) bolus pressure. The drug serves NDA after conducting several studies proving efficacy and safety.
Here’s what Gerri Henwood, President and CEO of Baudax Bio, has to say about BXRX share news.
“The approval of ANJESO marks a major step forward in the treatment landscape for managing moderate to severe pain. With our nation currently in the midst of a national opioid epidemic, we are proud to offer a new, non-opioid therapeutic alternative with the potential to meaningfully impact the acute pain management paradigm. ”
The news release Baudax Bio also reveals that the company is already preparing to launch the new drug. As long as everything goes well, it will be ready for patients in the United States starting in late April or early May.
The BRXR share increased by 15.44% as of Friday afternoon. The share has also increased by 20.98% since the beginning of the year.
At the time of writing, William White had no position in any of the above securities.
Article printed from InvestorPlace Media, https://investorplace.com/2020/02/baudax-bio-news-sends-bxrx-stock-soaring/.
© 2020 InvestorPlace Media, LLC